Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389717 | 1.00 | NPC1 (0.77) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL3807585 | 0.96 | NPC1 (0.71) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL15576719 | 0.95 | NPC1 (0.71) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL9609515 | 0.95 | NPC1 (0.71) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL9610736 | 0.95 | NPC1 (0.71) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL17765418 | 0.93 | NPC1 (0.74) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL1752680 | 0.93 | NPC1 (0.74) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL7075835 | 0.92 | NPC1 (0.65) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL7075840 | 0.92 | NPC1 (0.65) | NPC1MEN1KMT2ANPSR1LMNA | |
| SCHEMBL7726357 | 0.92 | NPC1 (0.72) | NPC1MEN1KMT2ANPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-2445870-B1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | INST UNIV CIENCIA I TECNOLOGIA (ES) | 2018-10-31 | — | — | EP | disclosed |
| US-8569507-B2 | N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECHNOLOGIA, S.A. (ES) | 2013-10-29 | — | — | US | disclosed |
| US-8569507-B2 | N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECHNOLOGIA, S.A. (ES) | 2013-10-29 | — | — | US | disclosed |
| US-8569507-B2 | N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECHNOLOGIA, S.A. (ES) | 2013-10-29 | — | — | US | disclosed |
| US-8455660-B2 | 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2013-06-04 | — | — | US | disclosed |
| US-8455660-B2 | 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2013-06-04 | — | — | US | disclosed |
| US-8455660-B2 | 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2013-06-04 | — | — | US | disclosed |
| US-20120142930-A1 | N-(2-OXO-1-PHENYLPIPERIDIN-3-YL)SULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | AMIRA THERAPEUTICS, S.L. (ES) | 2012-06-07 | — | — | US | disclosed |
| EP-2450349-A1 | N-(1-PHENYL-2-OXO-3-PIPERIDYL)SULPHONAMIDE LIBRARIES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2012-05-09 | — | — | EP | disclosed |
| EP-2447249-A1 | N-PHENYL-1-SULFONYL-2-PYRROLIDINE CARBOXAMIDE LIBRARIES FOR DRUG DISCOVERY | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2012-05-02 | — | — | EP | disclosed |
| EP-2447251-A1 | N-(1-PHENYL-2-OXO-3-PIPERIDYL SULPHONAMIDE LIBRARIES FOR DRUG DISCOVERY | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2012-05-02 | — | — | EP | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-1497273-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7589091-B2 | 2(R)-Benzyloxymethyl-4-[4-(4-chloro-phenyl)-piperazin-1-yl]-N-hydroxy-3(S)-(4-methoxy-phenyl)-4-oxo-butyramide; inhibiting matrix metalloproteinase; immunosuppression; neuropathic pain | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20060063778-A1 | Hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-03-23 | — | — | US | disclosed |
| EP-1497273-A2 | HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003084941-A2 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142930-A1 | N-(2-OXO-1-PHENYLPIPERIDIN-3-YL)SULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY | TPX2, TPST2, AADAC | NPC1 1530/4885MEN1 4514/4885KMT2A 3817/4885 |
| US-20060063778-A1 | Hydroxamic acid derivatives | HCAR1, HCAR2, TNF | NPC1 4604/4885MEN1 2877/4885KMT2A 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.